Drug Approval | February 20, 2025
Orchid Pharma's Alathur API facility successfully completes USFDA inspection
The Alathur facility specializes in the production of Cephalosporin antibiotics
The Alathur facility specializes in the production of Cephalosporin antibiotics
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders
EBITDA margins expand to 31.3%
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
In 2023, Endox had revenues of approximately SEK 65 million
Subscribe To Our Newsletter & Stay Updated
